Every Form 4 that Regentis Biomaterials Ltd. (RGNT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RGNT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGNT filings page.
Regentis Biomaterials Ltd. granted Director Susan Alpert an employee stock option for 24,826 Ordinary Shares at an exercise price of $2.16 per share. The grant, approved by the board on June 4, 2026 and subject to shareholder approval, became effective after shareholders approved it on July 9, 2026. The options vest in twelve quarterly installments starting September 4, 2026 and continue through June 4, 2029, and expire on June 4, 2036. Following this grant, Alpert holds options for 24,826 shares directly.
Regentis Biomaterials director Ben-Elazar Pini received two employee stock option grants covering 8,313 and 24,826 ordinary shares. The options have exercise prices of 0.0030 and 2.1600 per share; one grant is fully vested, while the other vests quarterly through June 4, 2029 under the 2024 Share Option Plan.
Valentine Keith reported acquisition or exercise transactions in this Form 4 filing.
Regentis Biomaterials Ltd. director Keith Valentine received a grant of 24,826 employee stock options to buy ordinary shares at $2.16 per share. The grant was approved by the board on May 28, 2026, subject to shareholder approval obtained July 9, 2026. The options vest in 12 quarterly installments starting August 28, 2026 and fully vest on May 28, 2029, and expire on May 28, 2036. Following this grant, Valentine holds options for 24,826 shares from this award.
Regentis Biomaterials director Jeff Dykan reported equity compensation consisting of 24,826 employee stock options with a $2.1600 exercise price and 12,500 warrants with a $0.0030 exercise price, each for ordinary shares. The options vest quarterly over three years until fully vested on May 28, 2029, while the warrants are currently exercisable for a three-year term through February 23, 2029. Both awards were approved by the board and became effective after shareholder approval on July 9, 2026.
REGENTIS BIOMATERIALS LTD. reports that its Chief Executive Officer, Ehud Geller, received a grant of 31,250 warrants to purchase an equal number of ordinary shares at an exercise price of $0.0030 per share. These currently exercisable warrants were approved by the board on February 23, 2026, received shareholder approval on July 9, 2026, and have a three-year term expiring on February 23, 2029. Following this award, Geller holds 31,250 warrants of this series directly.
Regentis Biomaterials Ltd. granted director Efraim Cohen-Arazi an employee stock option over 24,826 underlying ordinary shares at an exercise price of 2.1600 per share. The award vests in quarterly 1/12 installments from August 28, 2026 through May 28, 2029, subject to continued employment, and relates to the 2024 Share Option Plan, which may qualify for certain Israeli Section 102 tax benefits via trustee registration.